CLINICAL PHARMACY PRACTICE EXAM 300 QUESTIONS AND
CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED
ANSWERS) |ALREADY GRADED A+
• It refers to the responsible provision of drug therapy to achieve definite outcomes that are
intended to improve a client’s quality of life
• Professional-client’s relationship
• Therapeutic drug monitoring
• Drug therapy assessment
• Pharmaceutical care
• Formal documentation
• It involves measuring direct and indirect costs attributable to a specific disease
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• The method that allows for the identification, measurement, and comparison of the
benefits and costs of a program or treatment alternative
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• The method that involves the determination of the least costly alternative when
comparing two or more treatment alternatives
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• The method that integrates the client preferences and health-related quality of life
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• A way of summarizing the health benefits and resources used by competing health care
programs so that policy makers can choose among them
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
, • It refers to the value assigned to duration of life as modified by impairments, functional states,
perceptions and social opportunities that are influenced by disease, injury, treatment or policy
• Optimum health
• Quality of life
• Health outcomes
• Responsiveness
• Wellness of being
• A study design in which neither the study subject nor the study staff is aware of which
group or intervention the subjects has been assigned
• Randomized control trial
• Crossover study
• Cohort study
• Blinded study
• Cross-sectional study
• A retrospective comparison of causal factors or exposures in a group of persons with
disease and those of persons without the disease
• Randomized control trial
• Case control study
• Cohort study
• meta-analysis
• open-label trial
• A retrospective or prospective follow-up study of exposed and non-exposed defined groups in
which a variable of interest is measured
• Cross-sectional study
• Case control study
• Cross over study
• Cohort study
• open label trial
• A trial comparing treatments in which participants, on completion of one treatment, are
switched to the other
• Cross-sectional study
• Cross over study
• meta-analysis
• open label trial
• cohort study
• A study that examines the presence or absence of a disease and other variable in a
defined population and the potential risk factor at a particular point in time or time-interval
• Cross-sectional study
• Cohort study
• case control study
• cross over study
• case series
• Which of the following best describes the neonates?
• those who are 1 month to 1 year of age
• those who are 1 year to 12 years of age
• those who are 12 to 16 years of age
, • those between 1 day and 1 month
• those born before 32 weeks of gestational age
• Which of the following best describes the infant?
• those who are 1 month to 1 year of age
• those who are 1 year to 12 years of age
• those who are 12 to 16 years of age
• those between 1 day and 1 month
• those born before 32 weeks of gestational age
• Clinical manifestation of Gray Baby Syndrome include:
• Characteristic gray color III. Hypertension
• Abdominal distention IV. Progressive shock
• I only
• I and IV only
• I, II and III only
• I, II and IV only
• I and III only
• Which of the following is associated with the use of thalidomide?
• Polyneuritis III. Limb deformities
• Mental retardation
• I only
• I, II and III only
• II and III only
• III only
• I and III only
• Factors that increase the risk of drug-related problems in the elderly include:
• Polypharmacy III. Medication adherence
• Inappropriate prescribing IV. Multiple diseases
• I and II only
• I, II and III only
• II and IV only
• I, II and IV only
• I, II, III and IV
• Potential difficulties that may occur while taking medication histories from the elderly include:
• Impaired hearing III. Multiple diseases and medication
• Mental acuity IV. Reliance on a caregiver for the history
• I, II and III only
• I, III and IV only
• II, III and IV only
• I, II and IV only
• I, II, III and IV
• Refers to the continual monitoring for unwanted effects and other safety-related aspects of
marketed drugs
• Pharmacoepidemiology
• Pharmacovigilance
• Pharmacoinformatics
, • Pharmacogenetics
• Pharmacogenomics
• Study of the use of and effect of drugs in a large number of people
• Pharmacoepidemiology
• Pharmacovigilance
• Pharmacoinformatics
• Pharmacogenetics
• Pharmacogenomics
• Any noxious, unintended, and undesired effect of a drug that occurs at doses used in
humans for prophylaxis, diagnosis or therapy
• Adverse drug event
• Allergy
• Hypersensitivity
• Adverse drug reaction
• Idiosyncrasy
• Which of the following is/are true regarding chest x-ray?
• Provides supplemental information to the physical examination and usually the first
diagnostic test in a cardiac workup
• Provides details of internal cardiac structures
• Gives information about position and size of the heart and chambers and surrounding
anatomy
• I only
• I, II and III
• I and II only
• I and III only
• II and III only
• The manifestation of chromium deficiency include:
• Alopecia III. Red blood cell fragility
• Depigmentation of hair and skin IV. Glucose intolerance
• I and II only
• II and IV only
• I, II, III and VI
• III only
• IV only
• The manifestation of zinc deficiency include:
• Poor wound healing III. Poor resistance to infection
• Poor growth
• I only
• II and III only
• I and IV only
• III only
• I, II and III only
• Incompatibilities with fat emulsions cause majority of formulation problems in TPN.
Which of the following affects lipid stability in TPN preparations?
• Nature of amino acid solution III. The amount of dissolved oxygen in the
solution
• pH IV. Electrolyte content
CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED
ANSWERS) |ALREADY GRADED A+
• It refers to the responsible provision of drug therapy to achieve definite outcomes that are
intended to improve a client’s quality of life
• Professional-client’s relationship
• Therapeutic drug monitoring
• Drug therapy assessment
• Pharmaceutical care
• Formal documentation
• It involves measuring direct and indirect costs attributable to a specific disease
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• The method that allows for the identification, measurement, and comparison of the
benefits and costs of a program or treatment alternative
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• The method that involves the determination of the least costly alternative when
comparing two or more treatment alternatives
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• The method that integrates the client preferences and health-related quality of life
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
• A way of summarizing the health benefits and resources used by competing health care
programs so that policy makers can choose among them
• Cost-of-Illness Evaluation
• Cost-Effectiveness Analysis
• Cost-Minimization Analysis
• Cost-Utility Analysis
• Cost-Benefit Analysis
, • It refers to the value assigned to duration of life as modified by impairments, functional states,
perceptions and social opportunities that are influenced by disease, injury, treatment or policy
• Optimum health
• Quality of life
• Health outcomes
• Responsiveness
• Wellness of being
• A study design in which neither the study subject nor the study staff is aware of which
group or intervention the subjects has been assigned
• Randomized control trial
• Crossover study
• Cohort study
• Blinded study
• Cross-sectional study
• A retrospective comparison of causal factors or exposures in a group of persons with
disease and those of persons without the disease
• Randomized control trial
• Case control study
• Cohort study
• meta-analysis
• open-label trial
• A retrospective or prospective follow-up study of exposed and non-exposed defined groups in
which a variable of interest is measured
• Cross-sectional study
• Case control study
• Cross over study
• Cohort study
• open label trial
• A trial comparing treatments in which participants, on completion of one treatment, are
switched to the other
• Cross-sectional study
• Cross over study
• meta-analysis
• open label trial
• cohort study
• A study that examines the presence or absence of a disease and other variable in a
defined population and the potential risk factor at a particular point in time or time-interval
• Cross-sectional study
• Cohort study
• case control study
• cross over study
• case series
• Which of the following best describes the neonates?
• those who are 1 month to 1 year of age
• those who are 1 year to 12 years of age
• those who are 12 to 16 years of age
, • those between 1 day and 1 month
• those born before 32 weeks of gestational age
• Which of the following best describes the infant?
• those who are 1 month to 1 year of age
• those who are 1 year to 12 years of age
• those who are 12 to 16 years of age
• those between 1 day and 1 month
• those born before 32 weeks of gestational age
• Clinical manifestation of Gray Baby Syndrome include:
• Characteristic gray color III. Hypertension
• Abdominal distention IV. Progressive shock
• I only
• I and IV only
• I, II and III only
• I, II and IV only
• I and III only
• Which of the following is associated with the use of thalidomide?
• Polyneuritis III. Limb deformities
• Mental retardation
• I only
• I, II and III only
• II and III only
• III only
• I and III only
• Factors that increase the risk of drug-related problems in the elderly include:
• Polypharmacy III. Medication adherence
• Inappropriate prescribing IV. Multiple diseases
• I and II only
• I, II and III only
• II and IV only
• I, II and IV only
• I, II, III and IV
• Potential difficulties that may occur while taking medication histories from the elderly include:
• Impaired hearing III. Multiple diseases and medication
• Mental acuity IV. Reliance on a caregiver for the history
• I, II and III only
• I, III and IV only
• II, III and IV only
• I, II and IV only
• I, II, III and IV
• Refers to the continual monitoring for unwanted effects and other safety-related aspects of
marketed drugs
• Pharmacoepidemiology
• Pharmacovigilance
• Pharmacoinformatics
, • Pharmacogenetics
• Pharmacogenomics
• Study of the use of and effect of drugs in a large number of people
• Pharmacoepidemiology
• Pharmacovigilance
• Pharmacoinformatics
• Pharmacogenetics
• Pharmacogenomics
• Any noxious, unintended, and undesired effect of a drug that occurs at doses used in
humans for prophylaxis, diagnosis or therapy
• Adverse drug event
• Allergy
• Hypersensitivity
• Adverse drug reaction
• Idiosyncrasy
• Which of the following is/are true regarding chest x-ray?
• Provides supplemental information to the physical examination and usually the first
diagnostic test in a cardiac workup
• Provides details of internal cardiac structures
• Gives information about position and size of the heart and chambers and surrounding
anatomy
• I only
• I, II and III
• I and II only
• I and III only
• II and III only
• The manifestation of chromium deficiency include:
• Alopecia III. Red blood cell fragility
• Depigmentation of hair and skin IV. Glucose intolerance
• I and II only
• II and IV only
• I, II, III and VI
• III only
• IV only
• The manifestation of zinc deficiency include:
• Poor wound healing III. Poor resistance to infection
• Poor growth
• I only
• II and III only
• I and IV only
• III only
• I, II and III only
• Incompatibilities with fat emulsions cause majority of formulation problems in TPN.
Which of the following affects lipid stability in TPN preparations?
• Nature of amino acid solution III. The amount of dissolved oxygen in the
solution
• pH IV. Electrolyte content
